Drug discovery

#Astellas Pharma #Drug discovery #Interview #Ophthalmology

Astellas’ holistic strategy for drug discovery and development

Megan Thomas spoke to Leon Moore, Head of Global Brand Strategy & Marketing at Astellas, about how the company’s new Asset Maximization Teams are fostering collaboration and improving outcomes. MT: Astellas recently implemented a new structure, for its research, development and commercial teams to get innovative medicines to patients, faster. Read More

#Business & Investment #Exclusive Content

Structure of a molecule
#Drug discovery #Small molecules #Webinar

Quality drug candidates in under two years

Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects. Using its ‘Every Compound a Candidate (ECC)’ approach, Evotec is aiming to reduce timelines to under two years. This webinar on 10 November 2025 will explore the… Read More

Webinar date:
Supported by Evotec
#News

Cancer cells
#Chemotherapy #Drug discovery #Neuropathy #Oncology

Reducing the side-effects of chemotherapy  

DDW speaks to Yasuo Nakamura, Senior Executive Officer at Pharmaceuticals R&D, Asahi Kasei Pharma Corporation about the challenges of treating chemotherapy-induced peripheral neuropathy (CIPN) and the company’s current pipeline targeting the condition.   DDW: What makes chemotherapy-induced peripheral neuropathy (CIPN) such a persistent challenge in colorectal cancer care, and why has… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biomarkers #Drug discovery #Personalised medicine #Webinar

Innovative AI software solutions driving biomarker research

Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. This webinar, hosted by DDW and supported by Danaher Life Sciences, explores how advanced platforms such as Genedata Profiler… Read More

Webinar date:
Supported by Danaher
#Webinars

Structure of a molecule
#Drug discovery #Small molecules #Webinar

Quality drug candidates in under two years

Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects. Using its ‘Every Compound a Candidate (ECC)’ approach, Evotec is aiming to reduce timelines to under two years. This webinar will explore the current challenges facing small molecule… Read More

Webinar date:
Supported by Evotec
#Webinars

#AI #Antibody #Drug discovery #GPCRs

Abalone Bio talks opportunities for GPCR targets  

DDW Editor Reece Armstrong speaks to Richard Yu, CEO and Co-Founder of Abalone Bio about the company’s efforts to develop antibody antagonists for GPCR targets.  RA: What have been the biggest challenges of developing GPCR therapeutics?  RY: The number one challenge is specificity, and it plays out in a couple of… Read More

#Exclusive Content

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Organoids

Factsheet: Discover how organoids are advancing ADC research

Unlock insights into ADC development with HUB Organoids’ new factsheet on patient-derived organoids, available to download now. Discover how advanced 3D tumour models are transforming preclinical testing and supporting safer, more effective antibody-drug conjugates. What you’ll learn: How organoids outperform traditional preclinical models for ADCs Strategies for evaluating efficacy,… Read More

#News

#Antibody drug conjugate (ADC) #Drug discovery #Organoids

Advance Your ADC Research – Organoids Vs. Traditional Models

Unlock insights into ADC development with HUB Organoids’ factsheet on patient-derived organoids. Discover how advanced 3D tumour models are transforming preclinical testing and supporting safer, more effective antibody-drug conjugates. What you’ll learn: How organoids outperform traditional preclinical models for ADCs Strategies for evaluating efficacy, safety, and biomarker discovery Real-world case… Read More

#Resources

India on globe
#Drug development #Drug discovery #India #Investment

Syngene International commits new investment to drug discovery

Syngene International has announced new investment in peptide laboratory and advanced automation to accelerate drug discovery and development in India.  The investments include a dedicated peptide laboratory in Bengaluru and the integration of automation across Drug Metabolism and Pharmacokinetics (DMPK) and Direct-to-Biology (D2B) workflows in Hyderabad. The company hopes the… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Biomarkers #Drug discovery #Personalised medicine #Webinar

Webinar: Enhance the efficiency of your biomarker research

Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. Taking place on 23 October at 4pm BST, this webinar, hosted by DDW and supported by Danaher Life… Read More

Webinar date:
Supported by Danaher
#News

#Drug discovery #Genetics / genomics #Genome sequencing #Gut microbiome #Microbiology

Four therapeutic frontiers opened up by strain-level microbiome sequencing

Dr Jeremy Wilkinson, Microbial Genomics Lead, PacBio, explores how genomics are enabling higher-resolution microbiome profiling and highlights four therapeutic areas where this new layer of genomic precision is beginning to shape drug discovery and development.  Over the past decade, the gut microbiome has gone from a scientific curiosity to a… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Automation #Drug discovery #Organoids #Webinar

Standardising organoid workflows: How automation and AI enable reliable, scalable models

Organoids have emerged as powerful in vitro models in disease modelling, drug screening, and regenerative medicine, but their complexity introduces major workflow challenges, from culture variability to labour-intensive handling. This webinar, hosted by DDW and supported by Galatek, explores the evolving landscape of organoid research, identify common bottlenecks in daily… Read More

Webinar date:
Supported by Galatek
#Webinars

#DDW Turning Science into Business Symposium #Drug discovery #Events #The Francis Crick Institute

DDW Symposium: Full programme announced

Join DDW Editor Reece Armstrong and an expert line-up at the DDW Turning Science into Business Symposium at the Francis Crick Institute in London on Tuesday 4 November. This free half-day event will feature six in-depth presentations from industry experts, a panel discussion examining new… Read More

#News

#Drug discovery #Patent Law

From risk to resilience

Peng Fu, CEO, and Estrid Jakobsen, Communications Lead at Conscience, explore how creativity and open science are transforming drug discovery.   The traditional drug discovery model is showing signs of strain. The cost of developing new medicines continues to rise while early-stage funding is becoming harder to secure, timelines remain… Read More

#Exclusive Content